Weight May Alter Pediatric Asthma Drug Response

Key Takeaways

• In a systematic review of pediatric asthma treatment by weight status, inhaled corticosteroid-centered advantages appeared less consistent in children with overweight or obesity than in normal-weight peers.
• At GINA step 2, heavier children often showed similar or greater benefit with LTRA or nedocromil, while normal-weight children more often retained an ICS advantage.
• At step 3, LABA-containing combination therapy looked comparably protective across weight groups, whereas higher-dose ICS alone appeared less favorable in children with obesity.
• Post hoc biologic data suggested that omalizumab response was preserved or better in children with obesity, and a separate bronchodilator-response study linked obesity in Black and Latino children to more bronchodilator unresponsiveness.
• Differences in study design, obesity definitions, outcomes, and interaction reporting prevented pooled analysis, so firm recommendations were not possible; however, the authors suggested low-certainty (grade C) consideration of LTRA instead of ICS monotherapy, or LTRA/LABA add-on instead of higher-dose ICS, in overweight or obese children with suboptimal ICS response.

Children with asthma and excess weight often have greater morbidity, but it remains uncertain whether controller and step-up therapies work the same way across weight groups. That uncertainty matters when inhaled corticosteroid response appears variable and when alternative add-on options enter treatment decisions at different stages of disease control. To clarify those choices, investigators assembled pediatric comparisons of medication response by weight status across multiple treatment steps.

Investigators conducted a systematic review of pharmacologic asthma response by weight status in children using pediatric randomized controlled trials (RCTs), cohort studies, and case-control data from nonacute ambulatory settings. Searches covered PubMed, Embase, Latin American and Caribbean Literature on Health Sciences (LILACS), and the Cochrane Library from inception to 14 January 2025.

The review included 9 studies involving 7089 children, 33.9% of whom were overweight or obese: 1 randomized controlled trial, 5 post hoc analyses of randomized controlled trials, 2 retrospective cohorts, and 1 post hoc case-control analysis. Therapies were grouped by Global Initiative for Asthma (GINA) 2024 step, spanning step 1-2, step 2, step 3, step 5 biologic therapy, and bronchodilator response (BDR), with co-primary outcomes of exacerbations and symptoms and secondary outcomes including oral corticosteroid (OCS) use, acute care visits, lung function, BDR, and adverse effects. A narrative synthesis was used because differences in populations, interventions, obesity definitions, outcomes, and metrics precluded meta-analysis, and most studies were at low risk of bias, with 2 moderate-risk studies and 1 high-risk study.

Across the step-specific pediatric asthma treatment findings by weight status, the clearest signal at step 2 was that inhaled corticosteroid (ICS) superiority weakened as body weight increased. In the Childhood Asthma Management Program (CAMP), budesonide reduced emergency department visit or hospital admission risk by about 44% in nonoverweight children but not in overweight or obese children. In a Canadian cohort, each 10-unit increase in body mass index (BMI) percentile among leukotriene receptor antagonist (LTRA) users was associated with a 17% longer time to management failure (hazard ratio 0.83, 95% confidence interval [CI] 0.70-0.99), while low-dose ICS users showed no corresponding relationship. Other step 2 comparisons pointed in the same direction, with normal-weight children more often retaining an ICS advantage and heavier children sometimes doing as well as or better with LTRA or nedocromil.

Evidence beyond step 2 was thinner and mixed. At step 3, higher-dose ICS monotherapy appeared less favorable in obese children than LTRA- or long-acting β2-agonist (LABA)-containing regimens, while combination therapy looked similarly protective across weight groups in one cohort and the add-on montelukast trial was small and high risk of bias. For step 5 therapy, a post hoc Inner-City Anti-IgE Therapy for Asthma (ICATA) analysis showed greater monthly exacerbation reduction with omalizumab in obese than nonobese children (odds ratio [OR] 3.17 vs 1.46; interaction p=0.03). A separate bronchodilator-response analysis found 24% higher adjusted odds of bronchodilator unresponsiveness among obese Black and Latino children.

The authors did not support firm treatment recommendations because the evidence base was small, heterogeneous, and heavily dependent on post hoc subgroup analyses and retrospective cohorts, with inconsistent reporting of treatment-by-weight interactions. Obesity definitions varied across studies, one small step 3 randomized trial had high attrition and high risk of bias, adherence was not consistently measured, and safety reporting was limited. Neuropsychiatric effects related to montelukast were noted as a consideration by the authors, but those events were not specifically reported in the included pediatric studies.

Overall, the authors concluded that excess weight may modify pharmacologic response in pediatric asthma. The broad pattern was a reduced advantage for inhaled corticosteroids across some monotherapy and higher-dose step-up comparisons, alongside a similar or better response to omalizumab. Uncertainty remained because direct comparative data and treatment-by-weight interaction reporting were limited across the pediatric literature.

Clinician Questions

How was overweight or obesity defined across pediatric asthma drug-response studies?

Across the nine pediatric asthma studies, weight status was not defined with a single standard: five used Centers for Disease Control and Prevention percentile criteria, two used World Health Organization references, two did not specify the reference standard, and one omalizumab analysis used an absolute BMI cutoff rather than pediatric percentiles. That variation limited direct comparison across studies.

Did the review report safety outcomes for montelukast or other asthma therapies by weight status in children?

Adverse effects were prespecified secondary outcomes in the pediatric asthma review, but safety reporting was limited across the included studies. The authors identified montelukast neuropsychiatric effects as a consideration, yet those effects were not specifically reported in the reviewed pediatric studies.

What factors besides pharmacologic response may complicate lower ICS effectiveness in children with obesity and asthma?

The authors noted that adherence was not consistently measured in the included pediatric studies, which may complicate interpretation of lower ICS response in children with obesity and asthma. They also discussed psychosocial barriers, inhaler technique, comorbidity burden, and treatment complexity as possible contributors rather than proven effect modifiers within the review results.

Does the biologic signal in pediatric asthma and obesity extend beyond omalizumab?

Within this pediatric review, step 5 evidence was limited to post hoc omalizumab analyses, which suggested a similar or better response in obese children. The review did not provide comparable pediatric weight-stratified evidence for other biologic agents, so the observed signal remains omalizumab-specific.